Please use this identifier to cite or link to this item: https://doi.org/10.1158/1078-0432.CCR-10-3409
DC FieldValue
dc.titleA phase II study of pazopanib in asian patients with recurrent/metastatic nasopharyngeal carcinoma
dc.contributor.authorLim, W.-T.
dc.contributor.authorNg, Q.-S.
dc.contributor.authorIvy, P.
dc.contributor.authorLeong, S.-S.
dc.contributor.authorSingh, O.
dc.contributor.authorChowbay, B.
dc.contributor.authorGao, F.
dc.contributor.authorThng, C.H.
dc.contributor.authorGoh, B.-C.
dc.contributor.authorTan, D.S.-W.
dc.contributor.authorKoh, T.S.
dc.contributor.authorToh, C.-K.
dc.contributor.authorTan, E.-H.
dc.date.accessioned2016-09-06T03:01:47Z
dc.date.available2016-09-06T03:01:47Z
dc.date.issued2011-08-15
dc.identifier.citationLim, W.-T., Ng, Q.-S., Ivy, P., Leong, S.-S., Singh, O., Chowbay, B., Gao, F., Thng, C.H., Goh, B.-C., Tan, D.S.-W., Koh, T.S., Toh, C.-K., Tan, E.-H. (2011-08-15). A phase II study of pazopanib in asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clinical Cancer Research 17 (16) : 5481-5489. ScholarBank@NUS Repository. https://doi.org/10.1158/1078-0432.CCR-10-3409
dc.identifier.issn10780432
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/126599
dc.description.abstractPurpose: Nasopharyngeal carcinoma is endemic in Asia and angiogenesis is important for Growth and progression. We hypothesized that pazopanib would have antiangiogenic activity in nasopharyngeal carcinoma. Experimental Design: A single arm monotherapy study of pazopanib in patients with WHO type II/III nasopharyngeal carcinoma who had metastatic/recurrent disease and failed at least one line of chemotherapy. A Simon's optimal 2-stage design was used. Patients with Eastern Cooperative Oncology Group (ECOG) 0-2 and adequate organ function were treated with pazopanib 800 mg daily on a 21-day cycle. The primary endpoint was clinical benefit rate (CR/PR/SD) achieved after 12 weeks of treatment. Secondary endpoints included toxicity and progression-free survival. Exploratory studies of dynamic-contrast enhanced computed tomography (DCE-CT) paired with pharmacokinetics (PK) of pazopanib was done. Results: Thirty-three patients were accrued. Patients were ECOG 0-1 with median age of 50 years (range 36-68). There were 2 (6.1%) partial responses, 16 (48.5%) stable disease, 11 (33.3%) progressive disease, 4 (12.1%) were not evaluable for response. The clinical benefit rate was 54.5% (95% CI: 38.0-70.2). Ten patients (30.3%) received more than 6 cycles (4 months) of treatment and 7 (21.2%) had PR/SD that lasted at least 6 months. One patient each died from epistaxis and myocardial infarction. Common grade 3/4 toxicities included fatigue (15.2%), hand-foot syndrome (15.2%), anorexia (9.1%), diarrhea (6.1%), and vomiting (6.1%). Serial DCE-CT scans show significant reductions in tumor blood flow, permeability surface area product, and fractional intravascular blood volume. Conclusion: Pazopanib showed encouraging activity in heavily pretreated nasopharyngeal carcinoma with an acceptable toxicity profile. ©2011 AACR.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1158/1078-0432.CCR-10-3409
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentDUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.1158/1078-0432.CCR-10-3409
dc.description.sourcetitleClinical Cancer Research
dc.description.volume17
dc.description.issue16
dc.description.page5481-5489
dc.description.codenCCREF
dc.identifier.isiut000293843700028
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.